Immunovant slides as investors keep digesting Phase 3 batoclimab TED miss
Immunovant shares fell as traders continued to react to April 2, 2026 Phase 3 data showing batoclimab failed to meet primary endpoints in thyroid eye disease. The slide also reflects a risk-off reset in expectations for the pipeline while investors wait for later-stage readouts for IMVT-1402 later in 2026 and beyond.
1. What’s moving the stock today
Immunovant (IMVT) is trading lower as the market continues to price in disappointing late-stage results for batoclimab in thyroid eye disease (TED). On April 2, 2026, the company reported topline results from two Phase 3 “GO” studies in active, moderate-to-severe TED, and both studies failed to meet their primary endpoint, keeping pressure on the shares and driving ongoing de-risking flows in the days after the readout. (immunovant.com)
2. Why this matters (pipeline and sentiment)
The Phase 3 failure undercuts the near-term commercial narrative for batoclimab in TED and shifts investor focus back to the company’s next-generation FcRn program, IMVT-1402, where key value-driving data points are expected later in 2026 and beyond. With the next major clinical catalysts not immediately imminent, sentiment can swing on incremental news such as follow-on analyses, pipeline prioritization decisions, and investor positioning. (tipranks.com)
3. What to watch next
Investors will be watching for any clarity on batoclimab’s path forward in TED (including whether the company will pursue additional studies or reallocate resources) and for timing updates across IMVT-1402 programs. The next scheduled company-wide catalyst on many calendars is Immunovant’s next earnings report, currently listed for June 3, 2026 (before market open). (tipranks.com)